SCHEMBL3545303

SCHEMBL3545303

Brc1ccc[c]c1N1CCOCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
CYP2A13 Q16696 1/20 0.41
KDM4E B2RXH2 5/20 0.39
ALDH1A1 P00352 6/20 0.38
MAPT P10636 5/20 0.38
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
RAB9A P51151 3/20 0.38
HTT P42858 2/20 0.38
NPC1 O15118 2/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.37
HPGD P15428 3/20 0.35
HSD17B10 Q99714 3/20 0.35
ALOX15 P16050 2/20 0.35
MAPK1 P28482 2/20 0.33
GLA P06280 2/20 0.33
GAA P10253 2/20 0.33
TSHR P16473 2/20 0.33
USP2 O75604 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3541165 0.80 CNR2 (0.45) LMNACYP2A13ALDH1A1MAPTKMT2A
SCHEMBL3543532 0.79 ALDH1A1 (0.44) LMNACYP2A13KDM4EALDH1A1MAPT
SCHEMBL3543964 0.79 LMNA (0.41) LMNACYP2A13KDM4EALDH1A1MAPT
SCHEMBL28757513 0.79 LMNA (0.41) LMNAKDM4EALDH1A1MAPTKMT2A
SCHEMBL3545306 0.75 LMNA (0.41) LMNAKDM4EALDH1A1MAPTKMT2A
SCHEMBL5885356 0.75 CNR2 (0.45) LMNAKDM4EALDH1A1MAPTKMT2A
SCHEMBL2465608 0.75 CNR2 (0.45) LMNAKDM4EALDH1A1KMT2AMEN1
SCHEMBL3545361 0.75 KDM4E (0.44) LMNAKDM4EALDH1A1MAPTKMT2A
SCHEMBL8663809 0.73 KMT2A (0.43) LMNACYP2A13KDM4EALDH1A1MAPT
SCHEMBL30719587 0.69 LMNA (0.52) LMNACYP2A13KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US claimed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US claimed
EP-1833806-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2007-09-19 EP claimed
WO-2006064189-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 WO claimed
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed
EP-1833806-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2007-09-19 EP disclosed
WO-2006064189-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 LMNA 3296/4885CYP2A13 655/4885KDM4E 3511/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 LMNA 3477/4885CYP2A13 722/4885KDM4E 3382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.